- Home
- USAU vs TCRX Comparison
USAU vs TCRX Comparison
Compare USAU & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAU
- TCRX
- Stock Information
- Founded
- USAU 2014
- TCRX 2018
- Country
- USAU United States
- TCRX United States
- Employees
- USAU N/A
- TCRX N/A
- Industry
- USAU Precious Metals
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- USAU Basic Materials
- TCRX Health Care
- Exchange
- USAU Nasdaq
- TCRX Nasdaq
- Market Cap
- USAU 126.8M
- TCRX 140.7M
- IPO Year
- USAU N/A
- TCRX 2021
- Fundamental
- Price
- USAU $17.44
- TCRX $2.36
- Analyst Decision
- USAU Strong Buy
- TCRX Strong Buy
- Analyst Count
- USAU 3
- TCRX 5
- Target Price
- USAU $19.00
- TCRX $9.40
- AVG Volume (30 Days)
- USAU 430.6K
- TCRX 739.8K
- Earning Date
- USAU 09-15-2025
- TCRX 11-11-2025
- Dividend Yield
- USAU N/A
- TCRX N/A
- EPS Growth
- USAU N/A
- TCRX N/A
- EPS
- USAU N/A
- TCRX N/A
- Revenue
- USAU N/A
- TCRX $6,961,000.00
- Revenue This Year
- USAU N/A
- TCRX $255.18
- Revenue Next Year
- USAU N/A
- TCRX N/A
- P/E Ratio
- USAU N/A
- TCRX N/A
- Revenue Growth
- USAU N/A
- TCRX N/A
- 52 Week Low
- USAU $5.59
- TCRX $1.02
- 52 Week High
- USAU $19.20
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- USAU 54.17
- TCRX 61.96
- Support Level
- USAU $16.67
- TCRX $2.07
- Resistance Level
- USAU $19.05
- TCRX $2.57
- Average True Range (ATR)
- USAU 1.14
- TCRX 0.19
- MACD
- USAU -0.15
- TCRX 0.04
- Stochastic Oscillator
- USAU 45.35
- TCRX 68.66
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.